The reported collapse of the Xeinadin sale highlights a gap between firm expectations and market reality. Seeking a valuation of one billion pounds, the group aimed for a multiple significantly higher than recent industry benchmarks.
We discuss the challenges of aggregating independent firms and why true economies of scale are harder to achieve than they look on paper.
#digitoolsinaccrualworld #AppNews #accountingtechnews #fintechnews